A study in India on the immune response and safety of a respiratory syncytial virus (RSV) older adults (OA) vaccine when given to older adults 60 years of age and above and adults 50‑59 years of age at increased risk (AIR) of respiratory syncytial virus lower respiratory tract disease (RSV-LRTD)

Trial Identifier: 221265
Sponsor: GlaxoSmithKline
Start Date: October 2024
Primary Completion Date: June 2025
Study Completion Date: November 2025
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
INDIA Ahmedabad, INDIA, 380015
INDIA Ahmedabad, INDIA, 380061
INDIA Aligarh, INDIA, 202002
INDIA Bangalore, INDIA, 560002
INDIA Belagavi, INDIA, 590019
INDIA Darjeeling, INDIA, 734012
INDIA Delhi, INDIA, 110060
INDIA Kelambakkam, INDIA, 603103
INDIA Kochi, INDIA, 682026
INDIA Kolkata, INDIA, 700073
INDIA Pune-411 043, INDIA, 411043
INDIA Raipur, INDIA
INDIA Vadu Budruk Pune, INDIA, 412216
INDIA, Uttar Pradesh Kanpur, Uttar Pradesh, INDIA, 208002